Skip to main content

Table 2 Relationship between postchemotherapy absolute serum CA125 levels and survival in ovarian cancer

From: Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature

First Author, Year, Study Place Data Collection Study Design Sample Size Groups being Compared RR/HR, (95% CI), P-Value Conclusion Variables Adjusted for
Kim HS, 2008, South Korea [45] Jan 1997 to March 2007 Retrospective study 123 < 10 U/ml, 10--21 U/ml and > 21 U/ml 2.51(1.06-5.92), 0.027 3.13 (1.14-8.61), < 0.001 The serum CA125 level after 6 cycles of primary adjuvant paclitaxel/carboplatin chemotherapy may be a good prognostic factor for survival in complete responders Residual tumor, chemotherapy cycles
Juretzka MM, 2007, USA [46] 1984 to 1998 Retrospective cohort study 241 CA125 ≤ 12 U/ml vs > 12 U/ml 1.41 (1.05--1.91), 0.0248 CA125 level at the end of primary therapy was a predictor of overall survival and progression free survival FIGO stage, Histology, grade
Riedinger JM, 2007, France [47] 1988 to 1996 Multicentric retrospective study 494 ≤ 35 kU/l, > 35 kU/l Uni-2.7 (2.2--3.3), < 0.0001 Multi-1.27 (0.94--1.71), NS CA125 change after first course of chemotherapy was independent prognostic factor for both achievement of pathological complete response and overall survival. Age, Histology FIGO stage, residual tumor
Badulescu F, 2005, Romania [48] 2000 to 2002 Prospective study 40 NA NA, < 0.05 The response evaluation criteria based on the blood levels variations of CA125 antigen are a better instrument for the estimation of the compared prognosis with the RECIST criteria Age, FIGO stage, RECIST criteria
Van Dalen A, 2000, Europe [5] 1994 to 1997 Prospective multicentric study 213 ≤ 25 kU/L, > 25 kU/L 5.6 (2.65--11.90), < 0.0001 CA125 level of 25 kU/L on completion of three courses of chemotherapy is a good indicator of 2-year overall survival FIGO stage, Histology, grade, TPS levels
Ron IG, 1994, Israel [41] Feb 1987 to Dec 1990 Prospective study 48 ≤ 35 U/ml, > 35 U/ml NA, < 0.0001 Patients with CA125 below 35 U/ml after 2 courses had a significantly longer median and disease-free survival than those whose CA125 dropped to normal after the third or a later cycle Age, FIGO stage, histology, grade, residual tumor, ascites, prechemotherapy CA125
Fisken J, 1993, UK [49] NA Retrospective study 58 4 quartiles < 55 U/ml, 58-221 U/ml, 228-434 U/ml, > 450 U/ml < 0.0005 CA125 was a highly significant predictor of both progression free and overall survival after the first cycle and throughout primary chemotherapy Residual disease, age, tumor grade, performance status, ascites
Redman CW, 1990, U.K. [50] March 1986 to March 1988 Consecutive case series 50 ≤ 35 U/ml, > 35 U/ml NA, 0.0009 Serum CA125 after two courses gave the greatest discrimination between patients alive at 12 months and those who did not survive that long Age, FIGO stage, histology, grade, residual disease